Search Results (2)

Background: Monitoring pulse rate is fundamental to cardiovascular health management and early detection of rhythm disturbances. While oscillometric blood pressure measurement is well established and validated in clinical practice, its use for pulse rate monitoring, particularly via wrist-worn devices, remains largely unexplored. Objective: This study investigates whether a smartwatch that performs oscillometric blood pressure measurements at the wrist can also deliver reliable pulse rate readings using the same method. Methods: This study compared pulse rates recorded by the Omron HeartGuide smartwatch and conventional ambulatory blood pressure monitors in 50 patients over 24 h. Measurements were taken consecutively, and data were analyzed using intraclass correlation coefficients (ICCs) and Bland–Altman plots. Results: The study showed a high ICC of 0.971, indicating excellent agreement between devices. The average pulse rate difference was 1.5 bpm, with the Omron HeartGuide reporting slightly lower rates, especially in patients with atrial fibrillation. Conclusions: This study demonstrates that oscillometric pulse-rate monitoring at the wrist can achieve a high degree of accuracy, comparable to conventional upper-arm devices. Given that oscillometric smartwatches like the Omron HeartGuide are already used for blood pressure monitoring, the findings suggest that they may also be suitable for pulse rate measurement, potentially enhancing their role in telemetric healthcare, but further research is needed, particularly in patients with arrhythmias. Full article

Continuous high insulin levels are associated with weight gain and lead to cardiometabolic diseases. Therefore, we have developed the Low-Insulin-Method and integrated it into the multi-component, occupational healthcare program SHAPE-AND-MOTION-Medical-Accompanied-Slimming (SAMMAS) to reduce daily insulin levels for long-term weight reduction in overweight or obesity. Employees were randomized into a starting intervention group (SI, n = 15) or waiting list control group (WL, n = 15). SAMMAS consisted of group-based seminars, low-carbohydrate nutrition including formula diet, continuous glucose monitoring, telemetric monitoring, and telemedical coaching. Both groups received telemetric devices at baseline. Intention-to-treat analyses were performed after 12, 26, and 52 weeks. The estimated treatment difference in weight reduction after 12 weeks, which is the primary endpoint of the study, showed a pronounced effect in favour of SI (−6.3 kg with (95% confidence interval) (−7.4; −4.5) (p < 0.001)) after 12 weeks. Furthermore, SI improved fasting blood glucose, HbA1c, quality of life, fasting insulin, blood pressure, and eating behaviour (all p < 0.05) in the within-group analysis, while WL did not. After 26 and 52 weeks, weight reduction could be maintained in the whole group (both groups together) by −6.7 kg (−9.5; −3.8) (p < 0.001) and −6.1 kg (−9.2; −2.7) (p < 0.01). SAMMAS supports clinically relevant weight reduction and long-term weight loss maintenance in individuals with overweight or obesity. Full article